RMTI

Rockwell MedicalA

Nasdaq / Health Care Equipment & Services

At close

2026-06-03

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$1.45

+114.6% vs current

Most likely

Base case

50%

Probability

Target price

$0.85

+25.8% vs current

B-

Bear case

25%

Probability

Target price

$0.45

-33.4% vs current

AI sentiment snapshot

Latest data as of 2026-04-15

AI commentary

Sentiment is cautious-neutral. Primary sources support a monitoring view rather than a strong re-rating thesis: Rockwell has improved margins and cash generation, but forward visibility still depends on customer negotiations, contract execution, and proving that diversification can overcome prior volume losses from large accounts [#IR-2026-03-26] [#10-K-2026-03-26].

RankAlpha Sentiment Codex - 2026-04-15

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-07catalystQ1 2026 results on May 7 will test whether Q4 margin and cash gains are durableHigh impact

Rockwell said it will report first-quarter 2026 results on May 7, 2026. After Q4 2025 showed 21% gross margin, positive operating cash flow of $2.3 million, and year-end cash of $25.0 million, the next print is the clearest near-term check on whether the late-2025 operational improvement is holding despite prior revenue pressure from lower purchase volumes [#IR-2026-04-09] [#IR-2026-03-26] [#10-K-2026-03-26].

2026-09-30eventResolution of large-customer negotiations could unlock updated 2026 guidanceHigh impact

Management said on March 26, 2026 that it was negotiating with several large customers and planned to provide updated annual guidance after those discussions are resolved. That makes any contract announcement or refreshed sales/gross-margin outlook a discrete event, but visibility remains limited until the company discloses specifics [#IR-2026-03-26].

2026-12-31catalyst2026 contract execution must offset still-elevated customer concentration riskHigh impact

Rockwell extended a major dialysis-provider agreement through December 31, 2026 with pricing increases, but the 2025 10-K also shows DaVita still represented 16% of sales in 2025 after 45% in 2024. The long case depends on converting newer contracts and customer additions into steadier revenue so that pricing and mix gains are not overwhelmed by volume volatility [#IR-2026-01-05] [#10-K-2026-03-26] [#IR-2025-08-14].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-15 • Updated nightlySource: Internal modelMethodology